Collectively, these data confirm a key role for Egln3 in glioma progression through the hydroxylation of Hifs and through the participation of Egln3 in non-hydroxylase-dependent signaling pathways (see Discussion). This evidence concerns the gene EGLN3 and central nervous system cancer.